Algeria
African Region
I. Epidemiological profile
Population (UN)
Number of active foci
2015
%
-
Number of people living within active foci
Parasites and vectors
Plasmodium species:
P. falciparum (0%), P.vivax (0%)
An. multicolor, An. labranchiae, An. sergentii, An. hispaniola
-
-
Major anopheles species:
Malaria-free (0 cases)
36,900,000
-
Reported confirmed cases (health facility):
0
Total
36,900,000
Confirmed cases at community level:
-
Reported deaths:
1
Estimated cases:
0
Estimated deaths:
0
II. Intervention policies and strategies
Intervention
Policies/strategies
Yes/No
Adopted
ITN
ITNs/ LLINs distributed free of charge
No
ITNs/ LLINs distributed to all age groups
No
-
Yes
1980
No
IRS is recommended
IRS
Medicine
Year adopted
First-line treatment of unconfirmed malaria
-
-
First-line treatment of P. falciparum
-
-
Treatment failure of P. falciparum
-
-
-
Treatment of severe malaria
-
-
Yes
-
Treatment of P. vivax
CQ
-
DDT is authorized for IRS
Antimalarial treatment policy
Larval control
Use of larval control recommended
IPT
IPT used to prevent malaria during pregnancy
-
-
Dosage of Primaquine for radical treatment of P. vivax
Diagnosis
Patients of all ages should receive diagnostic test
-
-
Type pf RDT used
Yes
1968
-
-
Never allowed
-
Single dose of primaquine is used as gametocidal medicine for
P. falciparum
Yes
-
Primaquine is used for radical treatment of P. vivax
Yes
-
Therapeutic efficacy tests (clinical and parasitological failure, %)
No
-
Medicine
Yes
-
System for monitoring adverse reactions to antimalarials exists
No
-
ACD for case investigation (reactive)
Yes
-
ACD of febrile cases at community level (pro-active)
No
-
Mass screening is undertaken
No
-
Uncomplicated P. falciparum cases routinely admitted
No
-
Uncomplicated P. vivax cases routinely admitted
No
-
Foci and case investigation undertaken
Yes
1968
Case reporting from private sector is mandatory
Yes
-
Malaria diagnosis is free of charge in the public sector
Treatment
ACT is free of charge for all ages in public sector
The sale of oral artemisinin-based monotherapies (oAMTs)
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
Surveillance
III. Financing
0.25 mg/Kg (14 days)
-
Year
Min
Median
Max
Follow-up
No of studies
Species
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
Pyrethroid DDT Carbamate Organophosphate Species/complex tested
2010–2014
Sources of financing
Government expenditure by intervention in 2015
Contribution ($USm)
100
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and Evaluation
Human Resources & Technical Assistance
Management and other costs
80
60
40
20
Pie chart includes 100% of total expenditures
0
2008
2009
Gov. expend.
2010
Global Fund
2012
World Bank
IV. Coverage
USAID/PMI
2013
2014
WHO/UNICEF
2015
Others
Coverage of ITN and IRS
Cases tested
100
100
80
80
Supected cases (%)
Population (%)
2011
60
40
20
0
2005
2006
2007
2008
2009
2010
At high risk protected with ITNs
Households with at least one ITN (survey)
2011
2012
2013
2014
60
40
20
0
2005
2015
2006
2007
2008
2009
80
60
60
(%)
80
40
40
20
20
0
0
2008
2009
2010
Antimalarials distributed vs reported cases
Primaquine distributed vs reported P. v. cases
V. Impact
2011
2012
2013
2014
ACTs distributed vs reported P. f. cases
ACTs as % of all antimalarials received by <5 (survey)
2007
8
6
0.4
4
0.2
2
0
2008
2009
2010
ABER (microscopy & RDT)
RDT positivity rate
2014
2015
2011
2012
Slide positivity rate
Notes:
Reported confirmed cases and reported deaths are indigenous only
2013
2009
2010
2011
Cases investigated
2012
2013
2014
2015
Foci investigated
1,000
800
0.6
2007
2013
Number of malaria cases
0.8
2006
2008
Reporting completenes
2014
2015
Cases
Positivity rate (%)
2006
Confirmed malaria cases per 1000 and ABER
10
0
2005
2005
2015
ABER (%)
Case (%)
100
2007
2012
Cases tracked
100
2006
2011
All ages who slept under an ITN (survey)
At high risk protected with IRS
Cases treated
2005
2010
600
400
200
0
2005
2006
2007
Total cases
Indigenous case (P.vivax)
2008
2009
Imported cases
2010
2011
2012
2013
2014
Indigenous case (P.falciparum)
2015